# Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies

# Stephen R Marder1, Mika Juhani Hakala2, Mette Krog Josiassen2,Peter Zhang3, John Ouyang3, Emmanuelle Weiller2, Catherine Weiss3, Mary Hobart3

**Affiliations:** 1Semel Institute for Neuroscience at University of California Los Angeles, CA, USA; 2H. Lundbeck A/S, Valby, Denmark; 3Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, USA

**Corresponding author:** Dr S.R. Marder, 11301 Wilshire Blvd., MIRECC Building 210, Rm 130, Los Angeles, CA 90073, United States

e-mail: marder@ucla.edu

**Supplementary material**

**Table S1:** Mean (SD) change from baseline at last visit in extrapyramidal symptoms rating scales

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **SHORT-TERM STUDIES** | | | | | | **MAINTENANCE STUDY (Double-blind maintenance phase)** | | |
|  | **Flexible-dose study** | | | **Meta-analysisa** | | |
|  | **Placebo** | **Brexpiprazole 2–4 mg** | **Placebo** | | **Brexpiprazole 2–4 mg** | **Placebo** | | **Brexpiprazole 1–4 mg** |
| **Evaluation** | | | | | | | | |
| SAS | -0.2 (1.1)  (n=111) | -0.3 (1.3)  (n=114) | -0.1 (1.4)  (n=508) | | -0.1 (1.4)  (n=850) | -0.1 (0.9)  (n=104) | | -0.01 (0.6)  (n=96) |
| BARS | -0.02 (0.2)  (n=111) | -0.1 (0.4)  (n=114) | 0.0 (0.5)  (n=521) | | 0.0 (0.5)  (n=873) | -0.1 (0.5)  (n=104) | | -0.1 (0.3)  (n=96) |
| AIMS | 0.01 (0.6)  (n=111) | -0.2 (1.0)  (n=114) | -0.03 (0.8)  (n=520) | | -0.1 (0.9)  (n=873) | 0.1 (0.9)  (n=104) | | -0.03 (0.6)  (n=96) |

aPlacebo and brexpiprazole 2-4 mg groups from the two fixed-dose phase 3 studies and the one flexible-dose phase 3 study, were combined and analyzed using individual patient data meta-analysis

AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; SAS, Simpson Angus Scale; SD, standard deviation.